CNS|CRO Attending SfN 2016

Posted on Nov 11, 2016 in News & Events

Drs. Daphne Gill and Amber Marriott will be in San Diego November 12th – 16th for the Society for Neuroscience conference.  If you would like to learn more about how CNS|CRO can assist with your preclinical research projects, please contact Daphne by email at dagill@cnscro.com to arrange a meeting.

Read More

CNS|CRO presents poster at NHPRS Conference 2016

Posted on Jul 6, 2016 in News & Events

Amber Marriott, Research Scientist for CNS|CRO presents poster at NHPRS Conference 2016. (Photo credit: Sina Sedighi) The 13th annual meeting and conference of the Natural Health Product Research Society of Canada took place at the University of Prince Edward Island in Charlottetown from May 17 – 20, 2016. “From idea through commercialization – filling the gap in natural products research and development” was the theme of this year’s event. The event was held in conjunction with the NeuroConX Innovation Exchange, which incorporated neurodegenerative disease sessions on the brain and pain management. The event was held for the first time in Prince Edward Island and brought together individuals from all aspects of the natural health product industry, including the scientific team of CNS|CRO. Amber Marriott, a Research Scientist with CNS|CRO, presented a poster entitled, “CNS|CRO: Predictive Animal Models for Preclinical Research.” When asked how engaging with industry benefits students, Dr. Marriott replied: “The opportunity to engage with industry gives students a better understanding of the wide variety of potential career paths that exist for them and the opportunity to make contacts that will help them as they pursue their future goals,” says Marriott. The poster generated a lot of interest among conference delegates. It highlighted the company’s well-validated and highly predictive models including Parkinson’s disease, amyotrophic lateral sclerosis (ALS), epilepsy, and schizophrenia. These models are all slowly developing and progressive, thus providing greater accuracy in replicating human disease progression. The company is also well recognized for its new model development services, allowing for a fully customizable preclinical package. The three day conference concluded with a bio-partnering event hosted by the PEI BioAlliance, which facilitated even greater dialogue between interested parties on potential future joint research and/or commercialization ventures. About CNS|CRO: A wholly-owned subsidiary of Neurodyn Life Sciences Inc., CNS|CRO is a preclinical contract research organization offering a suite of animal models of neurological disease that are slowly developing and progressive, environmentally based, highly predictive, proprietary, and customizable. (Charlottetown, PE, June 28, 2016) For more information, please contact: Daphne Gill, PhD | Director of Operations | CNS|CRO T  902.628.4389 E...

Read More

CNS|CRO presents poster at NeuroConX Conference

Posted on Aug 25, 2015 in News & Events

(Charlottetown, PE | August 25, 2015) CNS|CRO was among other world-renowned researchers who shared their research services and findings at NeuroConX 2015, an international innovation exchange conference focused on neurodegenerative disorders, from July 12-14, 2015 in Charlottetown, Prince Edward Island. Now in its fifth year, the conference is presented by the PEI BioAlliance and Neurodyn Life Sciences Inc. The 2015 theme was Proteinopathies of Neurodegenerative Disorders. Daphne Gill, CNS|CRO’s Director of Operations, presented a poster on the preclinical neurological disease services of the contract research organization, including the latest portfolio of proprietary model offerings and development. “CNS|CRO’s competence, flexibility, and cost competitiveness are widely recognized,” says Gill. “This conference was an opportune occasion to demonstrate the strength of our models for replicating the human disease condition, and for translating scientific discoveries into more successful therapies.” New for 2015 is an autism spectrum disorder (ASD) behavioural test battery, an unparalleled method for assessing socio-communicative function in rats, as well as an electrophysiology platform for assessing sensory nerve conduction in vivo. This is in addition to a portfolio of highly predictive models of Parkinson’s disease, amyotrophic lateral sclerosis (ALS), epilepsy, and schizophrenia, as well as other conventional and proprietary behavioural tests. About CNS|CRO: A wholly-owned subsidiary of Neurodyn Life Sciences Inc., CNS|CRO is a preclinical contract research organization offering a suite of animal models of neurological disease that are slowly developing and progressive, environmentally based, highly predictive, proprietary, and customizable. For more information, please contact: Daphne Gill, PhD | Director of Operations | CNS|CRO T  902.628.4389 E...

Read More

PEI BIO Industry Hosts Neurological Health Symposium

Posted on Jul 2, 2013 in News & Events

The Prince Edward Island BioAlliance and Neurodyn will present the 4th Annual Biotechnology & Human Health Symposium, July 7- 9, 2013 at Rodd’s Brudenell River Resort, Prince Edward Island. The symposium will provide delegates insight into how inflammatory processes play an important role in the development of many neurological disease conditions and represent key therapeutic targets. The Biotechnology & Human Health Symposium program annually attracts international pharmaceutical companies, early stage companies, medical practitioners, principal investigators in clinical trials, contract research organizations, and investors who are focused on this therapeutic area. Dr. Jackalina Van Kampen, Director of Preclinical Research at Neurodyn Inc. and Adjunct Professor, Department of Biomedical Sciences at UPEI, is Program Chair of the Biotechnology and Human Health Symposium. She says the event will be one of the best yet. “This is shaping up to be a very exciting meeting. The concentration of talent that will be gathered here in PEI will give attendees access to some of the world leaders in our field of neurological research. We are very fortunate to attract speakers renowned in this area of research and I’m very proud to be a part of it.” This year’s event is being made possible with financial assistance of from the Government of Canada, through the Atlantic Canada Opportunities Agency (ACOA). “I am proud of our Government’s continued support for Atlantic Canada’s innovative bioscience sector. These investments help to build our region’s commercialization capacity and strengthen our economy,” said the Honourable Gail Shea, Minister of National Revenue and Minister for ACOA. “I encourage all attending delegates from Canada and around the world to have meaningful discussions and build strong relationships during the 4th Annual Biotechnology and Human Health Symposium.” This year’s program will feature a pre-symposium public lecture with Dr. Patrick McGeer from the University of British Columbia who will present “How to maintain a healthy brain and avoid dementia” on the evening of July 7th at 7:00 pm in Brudenell. The main program on July 8th and 9th will feature 12 leading researchers from across North America, Europe, Israel, and India who will present and discuss the role of neuro-inflammation and autoimmunity in the pathogenesis of neurological disease and the process of translating basic research into clinical practice. Canadian researchers and companies, such as Neurodyn, are doing important work in the areas of neurological disease prevention and therapy development. This Symposium gives local industry the opportunity to showcase the quality of work taking place in Atlantic Canada and provides key connections for industry representatives, as well as providing the general public with beneficial information on research, discoveries, and preventative measures for neurodegenerative diseases affecting Islanders. Organizers have also invited international pharmaceutical organizations, such as Johnson and Johnson and Genzyme, as well as...

Read More